GALDY · Galderma Group AG · Investor Relations

The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of Directors Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland --(BUSINESS WIRE)--Nov. 2, 2026-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults 1,2 The approval is based on phase

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland --(BUSINESS WIRE)--Oct. 22, 2026-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for the first

Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra ® and Restylane ®, and pooled phase III study data for Relfydess ® (relabotulinumtoxinA) 1-8 With 30 years of innovation, Restylane continues

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year 1 Currently, there are limited approved treatment options

Ad hoc announcement pursuant to Art. 53 LR Acquisition brings together two highly complementary, science-backed skincare brands ZO Skin Health’s premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio primarily focused on peri-procedure support Transaction expands

New clinical data identify optimized injectable aesthetics treatment protocol for menopause-induced skin changes 56% of women have experienced ‘The Menopausal Skin Misread’, admitting they first put menopause-related skin changes down to ageing, while fewer than a third (29%) recognized menopause

New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years 1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile

Galderma celebrates the 30 th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market 1 With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic

New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis 1 The findings, to

Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio ® (nemolizumab) clinical development program will explore long-term data, in line with

ZUG, Switzerland --(BUSINESS WIRE)--Sep. 21, 2026-- Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed

Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 12 1 Restylane Volyme was well tolerated, with no incidences of

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union ( EU) for chin augmentation 1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland --(BUSINESS WIRE)--Jul. 23, 2026-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD

Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive

World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin 1

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia,

Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment 1 Reliable clinical outcomes and robust

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland --(BUSINESS WIRE)--Apr. 23, 2026-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million

ZUG, Switzerland --(BUSINESS WIRE)--Apr. 22, 2026-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast.